Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study

BACKGROUND: Dose intense chemotherapy may improve efficacy with acceptable toxicity. A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC). METHODS: 49 patients with previ...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Christopher GCA, Sharples, Katrina, Thompson, Paul I, O’Donnell, Anne, Robinson, Bridget Anne, Perez, David J, Adams, Jacqui, Isaacs, Richard, Deva, Sanjeev, Hinder, Victoria A, Findlay, Michael P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192459/
https://www.ncbi.nlm.nih.gov/pubmed/25274181
http://dx.doi.org/10.1186/1471-2407-14-737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4192459/
https://www.ncbi.nlm.nih.gov/pubmed/25274181
http://dx.doi.org/10.1186/1471-2407-14-737

Ejemplares similares